Coriolis Pharma, a global service provider and a company involved in formulation R&D for (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, reported an investment from funds managed by KKR, a global investment firm. Coriolis Pharma will enter into a strategic growth partnership with Frontier Biosolutions, a global pharma services platform newly formed by KKR and Flerie Invest AB.

Coriolis Pharma has expertise in formulation research and development, analytical services and non-GMP manufacturing of innovative high-value biologics and cell and gene therapy products. Its scientific capabilities enable clients to create drug products with global commercial potential from the very beginning of the development process up to commercialization. KKR’s investment will enable Coriolis to initiate the next phase of growth in its core business, expand its service portfolio along the value chain, strengthen its presence globally, and continue to integrate AI-based technologies.

“We are very excited about this unique partnership which will help us to continue the Coriolis success story,” said Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “With KKR and Frontier Biosolutions, we have found quality-driven partners and industry experts who will support our excellent team to further expand our science-based services to our clients, whose needs will remain at the core of our activities.”